A new pooled analysis of the FIBRONEER™-IPF and FIBRONEER™-ILD trials resulted in a nominally significant reduction in the risk of death by 59% in patients who received 18mg nerandomilast without ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback